Appeal No. 94-4129
Application 07/953,439
(a) orally in solution, tablet or capsule form,
(b) subcutaneously or intravenously by injection, or
(c) intracerebroventricularly by implanted reservoir
(Davis, column 1, line 60, to column 2, line 44).
C. Physostigmine is useful in treating Alzheimer’s
Disease (Hille, column 1, lines 10-13);
D. Physostigmine may be administered to treat
Alzheimer’s Disease transdermally via an applicator comprising
(a) an impermeable backing layer, (b) a polymer matrix which
contains physostigmine and is connected to the backing layer,
and (c) a pressure-sensitive adhesive element for affixation
to the skin (Hille I, column 1, line 58, to column 3, line
26).
E. Galanthamine and physostigmine have
significantly different molecular formula, structural formula,
melting points, and solubility characteristics (Brief on
Appeal, page 6, citing The Merck Index, Tenth Edition, Merck &
Co., Inc.,
pages 620 and 1061-1065 (1983); see also Davis, column 1,
line 67, to column 2, line 2).
F. Galanthamine, physostigmine, and neostigmine are
known reversibly acting cholinesterase inhibitors with similar
- 6 -
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: November 3, 2007